HSG
ByteDance AI drug discovery spin-off Anew Labs raises $290M at $1.5B valuation
Anew Labs, ByteDance’s AI drug-discovery spin-off, has raised $290 million in its first external round at a valuation of about $1.5 billion.
Anew Labs, ByteDance’s AI drug-discovery spin-off, has raised $290 million in its first external round at a valuation of about $1.5 billion.
